DOCSLIB.ORG

Chem. Pharm. Bull. 66(6): 620-623 (2018)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chem. Pharm. Bull. 66(6): 620-623 (2018) 620 Chem. Pharm. Bull. 66, 620–623 (2018) Vol. 66, No. 6 Regular Article Chiral Recognition of Pharmaceuticals Having a Xanthine Skeleton by ()-Epigallocatechin-3-O-gallate in Water Hiroyuki Tsutsumi, Haruka Tanabe, and Takashi Ishizu* Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University; Sanzo Gakuen-cho 1, Fukuyama, Hiroshima 729–0292, Japan. Received January 16, 2018; accepted March 5, 2018 A mixture of pharmaceuticals having a xanthine skeleton, theophylline, proxyphylline, diprophylline and ()-epigallocatechin-3-O-gallate (EGCg) in water created a sticky precipitates, which were thought to be 2 : 2 complexes of the pharmaceuticals and EGCg. The molecular capture ability of the pharmaceuticals having a xanthine skeleton by EGCg was estimated by the amount of the pharmaceuticals included in the precipitates of the complexes, and measured by the integrated value of proton signals in the quantitative 1H-NMR spectra. Based on changes in chemical shifts of proton signals of the pharmaceuticals with a xan- thine skeleton in 1H-NMR spectra by adding standard amounts of EGCg, the xanthine skeleton of the phar- maceuticals was considered to exist in the hydrophobic space formed by the three aromatic A, B, B rings of EGCg, and a part of the proxyphylline and diprophylline side chains existed out of the hydrophobic space. In the 1H-NMR spectra of the mixture of (R)- and (S)-proxyphylline, (R)- and (S)-diprophylline and an equi- molecular amount of EGCg, the N3-CH3 signal of (R)- and (S)-proxyphylline, and (R)- and (S)-diprophylline was clearly observed as two singlets. This suggested that EGCg recognized the chirality of proxyphylline and diprophylline in water. Key words chiral recognition; (−)-epigallocatechin-3-O-gallate; 1H-NMR; pharmaceutical having xanthine skeleton; proxyphylline; diprophylline Catechins are a group of polyphenols that occur naturally in Pro residue.7) Based on the crystal structures of the 2 : 2 com- certain species of plants, including tea (Camellia sinensis, Ca- plexes of EGCg and cyclo(L-Pro-Gly), cyclo(D-Pro-Gly), such melliaceae), and are major ingredients in green tea infusions. a difference in chemical shift may have been due to magnetic The physiological activity and function of catechins have been anisotropic shielding effects by the ring current from the B studied by many researchers. The role of such molecules in the ring of EGCg (Fig. 1). prevention of cancer and cardiovascular disease has received However, the splitting of the methylene protons of the Pro a great deal of attention.1,2) Catechins may be scavengers of residue of cyclo(Pro-Gly) was difficult to observe in the chiral reactive oxygen species, which are thought to cause several recognition due to small differences in their chemical shifts diseases such as cancer, lifestyle diseases, aging, etc.3,4) and overlap of signals.7) In this report we applied chiral recog- We previously studied the molecular recognition, molecu- nition to pharmaceuticals, which are currently used in a race- lar capture, and asymmetric recognition of tea catechins in mic mixture. Thus, the chiral recognition of pharmaceuticals water. The gallated catechin (−)-epigallocatechin-3-O-gallate with a xanthine skeleton for bronchial asthma, proxyphylline (EGCg), which is most abundant in tea catechins, formed a and diprophylline were investigated using EGCg in water (Fig. hydrophobic space surrounding the top and lower walls of 2). As pharmaceuticals having a xanthine skeleton have two the B′ rings of EGCg, and right and left walls of the A and B methyl groups, which were observed as a sharp, strong singlet, rings of EGCg in water. Caffeine5) and nicotineamide,6) which the split of the methyl signal was considered as easy to ob- are also components of tea, were captured by the hydrophobic serve in 1H-NMR spectra. space formed by the three aromatic A, B, B′ rings of EGCg, and 2 : 2 complexes of EGCg were formed. As a result, the Experimental 2 : 2 complex precipitated from the aqueous solution due to its NMR Experiments 1H-NMR spectra were recorded with hydrophobicity. a JEOL JMN-LA500 (Tokyo, Japan) operating at 500 MHz. Furthermore, it was assumed that the space formed by the D2O (99.9 atom% D; Wako Pure Chemical Industries, Ltd.) three aromatic A, B, B′ rings of EGCg recognized the chiral- was used as a solvent. Chemical shift values are expressed ity of compounds included in the space because the C ring of in ppm downfield using sodium 2,2-dimethyl-2-silapentane- EGCg has two chiral carbon atoms, C2 and C3, and the hydro- 5-sulfonate (DSS) as an internal standard. The nuclear Over- phobic space formed by the three aromatic A, B, B′ rings of hauser effect (NOE) difference experiments were typically EGCg was a chiral space. conducted with 32 K data points covering a spectral width of On this assumption, we attempted the chiral recognition 10000 Hz and with ca. 5s presaturation time. 1 of diketopiperazines cyclo(L-Pro-Gly) and cyclo(D-Pro-Gly) Quantitative H-NMR (qNMR) Experiments qNMR by EGCg. Upon formation of 2 : 2 complexes of EGCg and was performed with the following optimized parameters: cyclo(L-Pro-Gly), cyclo(D-Pro-Gly) in D2O, the chirality of probe temperature, 25°C; spinning, off; number of scans, cyclo(Pro-Gly) was recognized by a difference in the chemi- eight; spectral width, 20 ppm; relaxation delay, 64 s; pulse 1 cal shift of H-NMR signal for some methylene protons of the angle, 90°; internal standard, DSS-d6 (Wako Pure Chemical * To whom correspondence should be addressed. e-mail: [email protected] © 2018 The Pharmaceutical Society of Japan Vol. 66, No. 6 (2018) Chem. Pharm. Bull. 621 Fig. 1. Intermolecular Interactions of 2 : 2 Complexes of EGCg and Cyclo(Pro-Gly) (a) 2 : 2 complex of EGCg and cyclo(L-Pro-Gly). (b) 2 : 2 complex of EGCg and cyclo(D-Pro-Gly). Black arrows and dotted lines indicate CH–π interactions and hydrogen bonds, respectively. Table 1. The Molecular Capture Ability of EGCg for the Pharmaceuti- cals Having a Xanthine Skeleton Xanthine derivative A (%) B Pyridine 49.47 1.000 Theophylline 86.60 1.751 Proxyphylline 79.32 1.603 Diprophylline 90.15 1.822 A: Mole number of each hetelocyclic compound in a crude precipitate/total mole number. B: A relative ratio when pyridine is set to 1.000. Fig. 2. Proxyphylline and Diprophylline Industries, Ltd.). Dimethyl sulfoxide (DMSO)-d6 (99.9 atom% D; Wako Pure Chemical Industries, Ltd.) was used as a sol- vent and DSS-d6 (Wako Pure Chemical Industries, Ltd.) was used as an internal standard. Preparation and qNMR of Sticky Precipitate Formed by EGCg and Pharmaceuticals Having a Xanthine Skel- eton EGCg (1.09×10−2 mmol) and pharmaceuticals having −2 a xanthine skeleton (1.09×10 mmol) were dissolved in D2O (70 µL) at 90°C, and left at room temperature for a day to ob- tain a supernatant liquid and sticky precipitate. After remov- ing the supernatant liquid, the sticky precipitate was evapo- rated under reduced pressure to create a residue. The residue was dissolved in DMSO-d6 (520 µL) contain- −3 ing DSS-d6 (1.44×10 mmol). The content of the resulting DMSO-d6 solutions was measured by qNMR with the methyl Fig. 3. The Chemical Shift Change of the Theophylline Protons by Adding EGCg group of DSS-d6 as an internal standard. Initial condition: the solution of theophylline (10 mM) in D2O at at 35°C. Results and Discussion Complex Formation of EGCg with the Pharmaceuticals of EGCg, and the pharmaceuticals having xanthine were cap- Having a Xanthine Skeleton Equimolecular amounts of tured in the hydrophobic space from the aqueous solution. pharmaceuticals having a xanthine skeleton, theophylline, The molecular capture ability of the pharmaceuticals with proxyphylline, diprophylline and EGCg in an aqueous solu- a xanthine skeleton by EGCg was estimated by the amount of tion divided into a supernatant liquid and a sticky precipitate, pharmaceuticals included in the precipitates of the complexes, which contained the pharmaceuticals with a xanthine skeleton which was measured by the integrated value of proton signals and EGCg at a molar ratio of 1 : 1 based on measurement of in the 1H-NMR spectra (Table 1). the integral volume of 1H-NMR signals. The precipitates were The Pharmaceuticals Having a Xanthine Skeleton in thought to be 2 : 2 complexes of the pharmaceuticals with the EGCg Complex Changes in chemical shifts of proton a xanthine skeleton and EGCg such as the 2 : 2 complex of signals of theophylline in 1H-NMR spectra by adding standard cyclo(Pro-Gly) and EGCg7) (Fig. 1). The 2 : 2 complexes had amounts of EGCg were observed. Upfield shifts in proton a hydrophobic space formed by three aromatic A, B, B′ rings signals for all protons N1-CH3, N3-CH3 and H8 were observed 622 Chem. Pharm. Bull. Vol. 66, No. 6 (2018) (Fig. 3). xanthine skeleton and C10 in its side chain were included in It was thought that the upfield shifts of proton signals re- the hydrophobic space formed by the three aromatic A, B, B′ sulted from the magnetic anisotropic shielding by the ring rings of EGCg in the 2 : 2 complex, and C11 and C12 of the side current from the B′ rings of EGCg, and the whole theophyl- chain existed out of the hydrophobic space, as shown in Fig. line molecule was captured by the hydrophobic space formed 6b. by EGCg, such as the cyclo(Pro-Gly) moieties of the 2 : 2 com- Similarly, changes in chemical shifts of proton signals of plex of cyclo(Pro-Gly) and EGCg, as shown in Figs. 1 and 6a. (R)- and (S)-diprophyllines8) in 1H-NMR spectra by add- Next, changes in chemical shifts of proton signals of (R)- ing standard amounts of EGCg were observed (Figs.
Load more

Recommended publications
  • SCH 58261: a Potent and Selective Non-Xanthine A2A Adenosine Receptor Antagonist
    22 DIRECTED DRUG DISCOVERY™ LIGAND-SETS™ for Assay Validation and High Throughput Screening Easy-to-use collections of pharmacologically-similar, small organic ligands Sigma-RBI LIGAND-SETS™ are a convenient and affordable way to screen a specific target with a collection of well- characterized, pharmacologically-active compounds. Each LIGAND-SET™ contains 40-80 high purity (>96%), small organic ligands arranged by pharmacological class in a 96-well format, one compound (2 mg) per well (1 ml capacity). N Standardize/validate new screening assays with well-characterized ligands N Guide secondary screening of larger, diverse libraries using pharmaceutically-relevant structures N Screen new drug targets for leads with pharmacologically-active compounds Nine different LIGAND-SETS™ are now available: N Adrenergics (Prod. No. L 0383) N Enzyme Inhibitors (Prod. No. L 6787) N Purines/Pyrimidines (Prod. No. L 2538) N Cholinergics (Prod. No. L 2663) N GABAergics (Prod. No. L 7884) N Glutamatergics (Prod. No. L 6537) N Dopaminergics (Prod. No. L 6412) N Ion Channel Modulators (Prod. No. L 6912) N Serotonergics (Prod. No. L 6662) For further information, please visit our Drug Discovery website at sigma-aldrich.com/drugdiscovery Technical information for each compound is provided in standard SD file format for use with ISIS/Base or other compatible software (software not provided). SCH 58261: A potent and selective non-xanthine A2A adenosine receptor antagonist Vol. 19 No. 4 Vol. Adenosine (Prod. No. A 9251) acts as a modulator of [3]. These results suggest a neuroprotective effect of this neuronal activity through its interaction with four receptor compound. In another study, the role of A1 and A2A subtypes referred to as A1, A2A, A2B and A3.
    [Show full text]
  • Aminophylline Catalog Number A1755 Storage
    Aminophylline Catalog Number A1755 Storage Temperature –20 °C Replacement for Catalog Number 216895 CAS RN 317-34-0 Storage/Stability Synonyms: theophylline hemiethylenediamine complex; Aminophylline should be kept tightly closed to prevent 3,7-dihydro-1,3-demethyl-1H-purine-2,6-dione CO2 absorption from the atmosphere, which leads to compound with 1,2-ethanediamine (2:1); formation of theophylline and decreased solubility in 1,2 3 (theophylline)2 • ethylenediamine aqueous solutions. Stock solutions should be protected from light and prevented from contact with Product Description metals.2 Molecular Formula: C7H8N4O2 ·1/2 (C2H8N2) Molecular Weight: 210.3 References 1. The Merck Index, 12th ed., Entry# 485. Aminophylline is a xanthine derivative which is a 2. Martindale: The Extra Pharmacopoeia, 31st ed., combination of theophylline and ethylenediamine that is Reynolds, J. E. F., ed., Royal Pharmaceutical more water soluble than theophylline alone. Society (London, England: 1996), pp. 1651-1652. Aminophylline has been widely used as an inhibitor of 3. Data for Biochemical Research, 3rd ed., Dawson, cAMP phosphodiesterase.3 R. M. C., et al., Oxford University Press (New York, NY: 1986), pp. 316-317. Aminophylline has been shown to limit 4. Pelech, S. L., et al., cAMP analogues inhibit phosphatidylcholine biosynthesis in cultured rat phosphatidylcholine biosynthesis in cultured rat hepatocytes.4 It has been used in studies of acute hepatocytes. J. Biol. Chem., 256(16), 8283-8286 hypoxemia in newborn and older guinea pigs.5 The (1981). effect of various xanthine derivatives, including 5. Crisanti, K. C., and Fewell, J. E., Aminophylline aminophylline, on activation of the cystic fibrosis alters the core temperature response to acute transmembrane conductance regulator (CFTR) chloride hypoxemia in newborn and older guinea pigs.
    [Show full text]
  • Effect of Theophylline and Enprofylline on Bronchial Hyperresponsiveness
    Thorax: first published as 10.1136/thx.44.12.1022 on 1 December 1989. Downloaded from Thorax 1989;44:1022-1026 Effect of theophylline and enprofylline on bronchial hyperresponsiveness G H KOETER, J KRAAN, M BOORSMA, J H G JONKMAN, TH W VAN DER MARK From the Department ofPulmonology and Lung Function, University Hospital, Groningen; Pharma Bio Research, Assen; and Astra Pharmaceutica, Rijswijk, The Netherlands ABSTRACT The effect of increasing intravenous doses of theophylline and enprofylline, a new xanthine derivative, on bronchial responsiveness to methacholine was studied in eight asthmatic patients. Methacholine provocations were carried out on three days before and after increasing doses of theophylline, enprofylline, and placebo, a double blind study design being used. Methacholine responsiveness was determined as the provocative concentration of methacholine causing a fall of 20% in FEV, (PC20). The patients were characterised pharmacokinetically before the main study to provide an individual dosage scheme for each patient that would provide rapid steady state plasma concentration plateaus of 5, 10, and 15 mg/l for theophylline and 1 25, 2 5, and 3-75 mg/l for enprofylline. Dose increments in the main study were given at 90 minute intervals. FEV, showed a small progressive decrease after placebo; it remained high in relation to placebo after both drugs and this effect was dose related. Methacholine PC20 values decreased after placebo; mean values were (maximum difference 2-0 and 1 7 higher after theophylline and enprofylline than after placebo copyright. doubling doses of methacholine); the effect of both drugs was dose related. Thus enprofylline and theophylline when given intravenously cause a small dose related increase in FEV1 and methacholine PC20 when compared with placebo.
    [Show full text]
  • Pro-Aging Effects of Xanthine Oxidoreductase Products
    antioxidants Review Pro-Aging Effects of Xanthine Oxidoreductase Products , , Maria Giulia Battelli y , Massimo Bortolotti y , Andrea Bolognesi * z and Letizia Polito * z Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy; [email protected] (M.G.B.); [email protected] (M.B.) * Correspondence: [email protected] (A.B.); [email protected] (L.P.); Tel.: +39-051-20-9-4707 (A.B.); +39-051-20-9-4729 (L.P.) These authors contributed equally. y Co-last authors. z Received: 22 July 2020; Accepted: 4 September 2020; Published: 8 September 2020 Abstract: The senescence process is the result of a series of factors that start from the genetic constitution interacting with epigenetic modifications induced by endogenous and environmental causes and that lead to a progressive deterioration at the cellular and functional levels. One of the main causes of aging is oxidative stress deriving from the imbalance between the production of reactive oxygen (ROS) and nitrogen (RNS) species and their scavenging through antioxidants. Xanthine oxidoreductase (XOR) activities produce uric acid, as well as reactive oxygen and nitrogen species, which all may be relevant to such equilibrium. This review analyzes XOR activity through in vitro experiments, animal studies and clinical reports, which highlight the pro-aging effects of XOR products. However, XOR activity contributes to a regular level of ROS and RNS, which appears essential for the proper functioning of many physiological pathways. This discourages the use of therapies with XOR inhibitors, unless symptomatic hyperuricemia is present.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • COPD Agents Review – October 2020 Page 2 | Proprietary Information
    COPD Agents Therapeutic Class Review (TCR) October 1, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. October 2020
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Proxyphylline Item No. 20937 CAS Registry No.: 603-00-9 Formal Name: 3,7-dihydro-7-(2-hydroxypropyl)-1,3- N dimethyl-1H-purine-2,6-dione O N Synonym: NSC 163343 C H N O MF: 10 14 4 3 N FW: 238.2 N Purity: ≥98% O UV/Vis.: λmax: 273, 324 nm Supplied as: A crystalline solid OH Storage: -20°C Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly Laboratory Procedures Proxyphylline is supplied as a crystalline solid. A stock solution may be made by dissolving the proxyphylline in the solvent of choice. Proxyphylline is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of proxyphylline in ethanol is approximately 1 mg/ml and approximately 10 mg/ml in DMSO and DMF. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of proxyphylline can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of proxyphylline in PBS, pH 7.2, is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day. Description Proxyphylline is a methylxanthine derivative that has bronchodilatory actions.1 It has also been reported 2 to have vasodilatory and cardiac stimulatory effects.
    [Show full text]
  • The Latin Language and Medical Terminology
    T. Titiyevska, O. Gordiyenko, A. Kulichenko THE LATIN LANGUAGE AND MEDICAL TERMINOLOGY QUIZZES AND TASKS FOR PRACTICAL SKILLS EVALUATION for the First-Year Students of the Medical Faculties with the English Medium of Instruction, Specialty 222 “General Medicine” Zaporizhzhia 2019 1 Zaporizhzhia State Medical University Department of Foreign Languages T. Titiyevska, O. Gordiyenko, A. Kulichenko THE LATIN LANGUAGE AND MEDICAL TERMINOLOGY QUIZZES AND TASKS FOR PRACTICAL SKILLS EVALUATION for the First-Year Students of the Medical Faculties with the English Medium of Instruction, Specialty 222 “General Medicine” Zaporizhzhia 2019 2 UDC 811.124:[001.4:61](076.1) T64 A manual is approved and recommended for using in learning process by the Central Methodical Commission of Zaporizhzhia State Medical University (record No. 1 from September 26, 2019). Reviewers: S. Chugin, PhD (Medicine), Associate Professor, Department of Human Anatomy, Operative Surgery and Topographic Anatomy, Zaporizhzhia State Medical University. R. Shramko, PhD (Philology), Associate Professor, Department of English and German Philology, Poltava V.G. Korolenko National Pedagogical University. Authors: T. Titiyevska, Senior Lecturer, Department of Foreign Languages, Zaporizhzhia State Medical University. O. Gordiyenko, PhD (Philology), Associate Professor, Department of Foreign Languages, Zaporizhzhia State Medical University. A. Kulichenko, PhD (Pedagogics), Associate Professor, Department of Foreign Languages, Zaporizhzhia State Medical University. Е The Latin Language and Medical Terminology. Quizzes and Tasks for Practical Skills Evaluation for the First-Year Students of the Medical Faculties with the English Medium of Instruction, specialty 222 “General Medicine” = Латинська T64 мова та медична термінологія. Зб. завд. для самост. роб. та завд. для перев. практ. навич. у студ.-іноз.
    [Show full text]
  • Comparing Retention in Xanthines Separation Between a Silica and Titania Stationary Phase in HPLC
    22 General Comparing retention in xanthines separation between a silica and titania stationary phase in HPLC Agnieszka PIWIEN Introduction The Objective of analytical chemistry is to determine chemical composi- Fig.1. Dependence of retention factor Lnk to % tions. of ACN in mobile phase in Aquasil column, Nowadays, it mostly relies on instrumental methods. Research conditions: !ow rate 200μL/min, ACN-Water (v/v) focuses on discovering new materials and chromatography principles. Columns with a silica layer are currently being used as a stationary phase in high performance liquid chromatography (HPLC). Owing to their low mechanical, thermal and pH stability the scientists are forced to investi- gate the different column supports. Therefore, the study on titanium support column was performed on the grounds of its strong Lewis acid sites probably resistant to changes of pH. The aim of these experiments was to compare the effectiveness of these two columns. Experimental methods First of all the xanthines and their derivatives were analyzed in the silica column Aquasil (50mm x 2,1mm I.D., 1,9m) in RPLC mode then in the Fig.2. Dependence of retention factor Lnk to % titanium dioxide column SachtoporeNP (100mm x 2,1mm I.D., 5m) in of water in mobile phase in Sachtopore column, HILIC mode. The Titania column was also studied under the influence of a conditions: !ow rate 200μL/min, ACN-Water mobile phase with and without a buffer solution. (v/v) All solutions were prepared using deionized water (Elga LAB WATER) and acetonitrile in a 1:1 (v/v) ratio. Uracile and naphthalene were respectively used as dead time markers, the former in the RP mode and the latter in HILIC mode (Hydrophilic interaction liquid chromatography).
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0304998 A1 Sem (43) Pub
    US 20100304998A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0304998 A1 Sem (43) Pub. Date: Dec. 2, 2010 (54) CHEMICAL PROTEOMIC ASSAY FOR Related U.S. Application Data OPTIMIZING DRUG BINDING TO TARGET (60) Provisional application No. 61/217,585, filed on Jun. PROTEINS 2, 2009. (75) Inventor: Daniel S. Sem, New Berlin, WI Publication Classification (US) (51) Int. C. GOIN 33/545 (2006.01) Correspondence Address: GOIN 27/26 (2006.01) ANDRUS, SCEALES, STARKE & SAWALL, LLP C40B 30/04 (2006.01) 100 EAST WISCONSINAVENUE, SUITE 1100 (52) U.S. Cl. ............... 506/9: 436/531; 204/456; 435/7.1 MILWAUKEE, WI 53202 (US) (57) ABSTRACT (73) Assignee: MARQUETTE UNIVERSITY, Disclosed herein are methods related to drug development. Milwaukee, WI (US) The methods typically include steps whereby an existing drug is modified to obtain a derivative form or whereby an analog (21) Appl. No.: 12/792,398 of an existing drug is identified in order to obtain a new therapeutic agent that preferably has a higher efficacy and (22) Filed: Jun. 2, 2010 fewer side effects than the existing drug. Patent Application Publication Dec. 2, 2010 Sheet 1 of 22 US 2010/0304998 A1 augavpop, Patent Application Publication Dec. 2, 2010 Sheet 2 of 22 US 2010/0304998 A1 g Patent Application Publication Dec. 2, 2010 Sheet 3 of 22 US 2010/0304998 A1 Patent Application Publication Dec. 2, 2010 Sheet 4 of 22 US 2010/0304998 A1 tg & Patent Application Publication Dec. 2, 2010 Sheet 5 of 22 US 2010/0304998 A1 Patent Application Publication Dec.
    [Show full text]